实用肿瘤杂志2013，Vol.28Issue(4)：378-381,4.
DC-CIK治疗晚期非小细胞肺癌的近期临床疗效观察
Clinical efficacy of DC-CIK treatment for advanced non-small cell lung cancer
王丹红 1高海燕 1张斌 2吴琼 2丁国梁 2张婧 2侯彩艳 1艾建红 1陈虎1
作者信息
- 1. 军事医学科学院附属医院全军造血干细胞移植研究所,北京100071
- 2. 军事医学科学院细胞与基因治疗中心,北京100071
- 折叠
摘要
Abstract
Objective To evaluate the safety and clinical efficacy of dendritic cell (DC)-cytokine induced killer cell (CIK) treatment for advanced non-small cell lung cancer(NSCLC).Methods Thirty-four NSCLC patients treated with DC-CIK were eligible for evaluation.The clinical efficacy,immune function,quality of life and toxicity were evaluated.Results The objective response rate (ORR) was 20.6％ and the disease control rate (DCR) was 67.6％ after 1-3 months of treatment.The ORR and DCR were not correlated with the status of metastasis (P ＞ O.05).The number of DC-CIK treatment was not correlated with the ORR(P ＞ 0.05),but it was correlated with the DCR(P ＜ 0.05).No notable side effects were observed.Conclusion Treatment with DC-CIK cells is safe and effective for advanced NSCLC,and it can also improve quality of life and reduce the probability of metastasis and recurrence for patients.关键词
癌,非小细胞肺/治疗/免疫疗法/方法/树突细胞/免疫学/杀伤细胞,淋巴因子激活/免疫学/治疗结果Key words
carcinoma, non-small-cell lung/therapy/immunotherapy/methods/dendritic cells/immunology/killer cells,lymphokine-activated/immunology/treatment outcome分类
医药卫生引用本文复制引用
王丹红,高海燕,张斌,吴琼,丁国梁,张婧,侯彩艳,艾建红,陈虎..DC-CIK治疗晚期非小细胞肺癌的近期临床疗效观察[J].实用肿瘤杂志,2013,28(4):378-381,4.
